img
:::

Popular weight-loss and diabetes medications linked to lower risk of some cancers, study finds

GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests. / PickPik
GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests. / PickPik

GLP-1 medications such as Ozempic and Wegovy may help lower the risk of certain cancers, a new study suggests.

People who are overweight or obese have a higher risk of getting 13 types of cancer, and the risk increases the longer a person is overweight and the more excess weight they gain. About 40% of new cancer diagnoses are associated with excess weight, according to the US Centers for Disease Control and Prevention. In 2021, there were about 170 new diagnoses for every 100,000 people, CDC data shows.

The risk was cut by more than half for gallbladder cancer, meningioma, pancreatic cancer and hepatocellular carcinoma, a kind of liver cancer. It was also significantly reduced for ovarian cancer, colorectal cancer, multiple myeloma, esophageal cancer, endometrial cancer and kidney cancer.

Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer,/The Blue Diamond Gallery 

Excess weight can cause changes in the body such as long-lasting inflammation and higher than normal levels of insulin, insulin-like growth factor and sex hormones that can cause cancer, according to the CDC. And GLP-1 medications interact with systems related to insulin production.

The new findings that link GLP-1 treatment to reduced risk of some cancers “compare favorably” with similar effects linked to intensive lifestyle intervention and metabolic-bariatric surgery that have been found in other trials, the study authors wrote.

For this study, researchers from the Case Western Reserve University School of Medicine and the MetroHealth System analyzed more than a decade of medical records for nearly 1.7 million people with type 2 diabetes.

More information is needed about how reduced cancer risk may relate to the scale of weight loss, but the findings provide “preliminary evidence of the potential benefit of GLP-1RAs for cancer prevention in high-risk populations and support further preclinical and clinical studies,” the study authors wrote.

First Response

Anoo I want to reduce weight as i have higher BMI and I want to participate in clinical trails for obesity to know which works forme

回覆
57天前

Popular News

Latest News 最新消息icon
回到頁首icon
Loading